Europe PMC
Cure8 research brief
Why This Matters
This method could let researchers study human intestinal tissue and its immune environment directly, potentially improving understanding of IBD mechanisms and how individual patients’ tissues respond to therapies.
That could accelerate development and testing of personalized treatments using real patient tissue rather than animal or simplified in vitro models.
Who Should Pay Attention
Researchers studying IBD pathogenesis or drug development; translational clinicians interested in ex vivo human tissue models; patients and advocates interested in research tools that could enable personalized therapy testing in the future.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This preprint describes a custom normothermic machine perfusion (NMP) platform that can maintain surgically resected human intestinal segments ex vivo for up to 72 hours under near-physiological conditions.
The authors report preserved mucosal architecture, epithelial integrity, oxygen consumption, metabolic activity, and vascular patency, with daily perfusate sampling used to profile inflammatory mediators and reveal patient-specific immune states.
The work is presented as a tool bridging simple in vitro models and clinical disease, intended to enable mechanistic studies of intestinal inflammation and to test therapies on intact patient-derived tissue. The platform used discarded surgical specimens from patients with nonmalignant intestinal disease, including some with IBD.
Because the supplied content is an abstract from a preprint, these findings have not completed peer review and the extraction is limited to the abstract.
The abstract supports that the platform preserves tissue viability and allows longitudinal molecular sampling, but it does not provide full experimental details, statistical analyses, or clinical-grade validation.
If you are a patient or caregiver, this does not describe a new treatment; rather it is a laboratory model that may speed research on personalized approaches in the future.
Keep In Mind
This is a preprint abstract (not peer-reviewed) and the extracted content is an abstract-level summary. The platform was tested on discarded surgical specimens; it is presented as a research tool rather than a clinical therapy. Full methods, raw data, and peer review are needed to judge robustness and reproducibility.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationEurope PMC
AuthorsUrbina PAM, Choi SR, Cheung DC +14 more
Study typePreprint
Indexed viaEurope PMC
Source typeResearch paper
PublishedSep 18, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Short-term culture of human endoscopic specimens for the study of chronic inflammation.
Researchers can use these human tissue slice cultures to study inflammation and test drugs on a patient’s own biopsy tissue, which could eventually help explain treatment response or resistance in IBD and related...
A Centimeter-Scale, Peristaltic Human Intestinal Organoid with Integrated Neuro-Immune-Vascular Systems Recapitulates Enteritis and Orthotopic Colorectal Cancer
This model could improve how researchers study IBD inflammation and early colorectal cancer in a human-derived, multicellular system that reproduces neuromuscular function and immune responses. That may speed preclinical...
A scalable microarrayed organoid platform for precision modeling of intestinal epithelial damage and recovery.
An organoid platform that models epithelial injury and recovery could help researchers test treatments and biomarkers more precisely and at scale, accelerating work relevant to Crohn’s disease and other IBDs.